Related Experiment Videos
RAF antisense oligonucleotide as a tumor radiosensitizer
Usha Kasid1, Anatoly Dritschilo
1Department of Radiation Medicine, Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA.
Oncogene
|August 30, 2003
Summary
Targeting RAF-1 signaling with antisense oligonucleotides shows promise for cancer therapy. Liposomal encapsulation improves delivery and stability, overcoming previous challenges for clinical application.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- RAF-1 kinase is crucial in cell survival and proliferation signaling pathways.
- Targeting RAF-1 has been explored for cancer therapy since 1989, demonstrating tumor inhibition.
- Clinical application of antisense strategies was limited by technology and delivery challenges.
Purpose of the Study:
- To review the significance of targeting RAF-1 signaling in cancer.
- To discuss preclinical and clinical data of a liposomal antisense RAF oligonucleotide.
Main Methods:
- Review of literature on RAF-1 signaling and antisense oligonucleotide technology.
- Evaluation of liposomal encapsulation as a drug delivery method for antisense oligonucleotides.
- Analysis of preclinical and clinical studies involving a specific liposomal formulation.
Main Results:
- Liposomal encapsulation protects nuclease-sensitive oligonucleotides from degradation.
- Improved delivery and stability of antisense oligonucleotides enhance therapeutic potential.
- Preclinical and clinical data support the efficacy of liposomal antisense RAF oligonucleotide.
Conclusions:
- Targeting RAF-1 signaling is a viable strategy for cancer treatment.
- Liposomal delivery systems overcome major hurdles for antisense oligonucleotide therapy.
- Further clinical development of liposomal antisense RAF oligonucleotides is warranted.